Exelixis | EXEL - 부채





부채 변화 날짜
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 44.52M 4.24M 2025-09
Akebia Therapeutics USD 46.51M 7.82M 2025-03
Amgen USD 54.59B 1.62B 2025-09
AstraZeneca USD 32.63B 207M 2025-09
Bayer EUR 39.39B 1.31B 2025-03
BioMarin Pharmaceutical USD 604.24M 375K 2025-09
Bristol-Myers Squibb USD 51.04B 112M 2025-09
Cytokinetics USD 1.2B 338.79M 2025-09
Eisai JPY 236.67B 49.14B 2025-09
Eli Lilly USD 42.51B 2.6B 2025-09
Esperion Therapeutics USD 262.92M 1.76M 2024-09
Exelixis USD 176.46M 3.38M 2025-09
Genmab DKK 148M 5M 2025-06
Glaxosmithkline GBP 17.75B 396M 2025-09
Incyte USD 40.41M 855K 2025-12
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
MacroGenics USD 37.01M 238K 2025-09
Merck USD 41.37B 5.97B 2025-09
Moderna USD 734M 7M 2025-09
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
Novartis USD 32.64B 1.37B 2025-06
Pfizer USD 60.85B 78M 2025-09
Puma Biotechnology USD 89.06M 55.07M 2024-06
Sanofi EUR 21.76B 530M 2025-09
Takeda JPY 4.85T 208B 2025-12
Ultragenyx Pharmaceutical USD 33.83M 2.46M 2025-09
Xencor USD 69.27M 1.34M 2025-09